Figure 2
Poly-ICLC administration enhances vaccine-induced specific CTL generation in vivo. (A), C57BL/6 mice received OVA-vaccines with or without i.m. poly-ICLC on days 0 and 7 (n = 3/group). OVA-specific CD8+ T cell activities in SPC (a) and draining inguinal LN cells (b) were evaluated by in vivo CTL assays on day 14. *P < 0.01 for the combination group compared with poly-ICLC alone or control group; and P < 0.05 for the combination group compared with vaccine alone group. #P > 0.05 for the group receiving vaccine alone compared with poly-ICLC alone or control group. (B), C57BL/6 mice received GAA-vaccines with or without i.m. poly-ICLC on days 0 and 7. SPCs were harvested on day 14. Following a 5-day in vitro stimulation with 20 IU/ml IL-2 and three GAA peptides, SPCs were tested for their lytic activity against GL261 glioma cells (a) or EL4 cells (b) in a 4-hr standard 51Cr-release assay. (C), C57BL/6 mice received EphA2-vaccines with or without i.m. poly-ICLC on days 0 and 7. On day 14, SPC were harvested, in vitro stimulated with low-dose (20 IU/ml) hIL-2 and mEphA2671–679 for 5 days prior to performance of mouse IFN-γ specific ELISA using culture-supernatants. *P < 0.001 compared to vaccine alone, poly-ICLC alone and the control groups. For (A-C), n = 3/group, and data represent results from one of 3 independent experiments performed with similar results obtained. Error bars represent standard deviation (SD).